Foundations Investment Advisors LLC Reduces Stock Position in Pfizer Inc. $PFE

Foundations Investment Advisors LLC decreased its position in shares of Pfizer Inc. (NYSE:PFE) by 48.4% during the 3rd quarter, Holdings Channel.com reports. The fund owned 39,228 shares of the biopharmaceutical company’s stock after selling 36,816 shares during the period. Foundations Investment Advisors LLC’s holdings in Pfizer were worth $1,000,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Ruffer LLP raised its holdings in Pfizer by 44.6% during the third quarter. Ruffer LLP now owns 2,023,065 shares of the biopharmaceutical company’s stock worth $51,547,000 after purchasing an additional 623,552 shares during the last quarter. AE Wealth Management LLC boosted its position in shares of Pfizer by 5.6% in the 3rd quarter. AE Wealth Management LLC now owns 1,238,460 shares of the biopharmaceutical company’s stock worth $31,556,000 after buying an additional 65,682 shares in the last quarter. Archer Investment Corp boosted its position in shares of Pfizer by 37.0% in the 3rd quarter. Archer Investment Corp now owns 67,672 shares of the biopharmaceutical company’s stock worth $1,724,000 after buying an additional 18,281 shares in the last quarter. Addison Capital Co acquired a new stake in Pfizer in the 3rd quarter valued at about $683,000. Finally, Activest Wealth Management increased its holdings in Pfizer by 20.9% during the 3rd quarter. Activest Wealth Management now owns 24,815 shares of the biopharmaceutical company’s stock valued at $632,000 after acquiring an additional 4,293 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Price Performance

PFE opened at $26.43 on Friday. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $27.69. The company’s 50 day simple moving average is $25.52 and its 200 day simple moving average is $25.03. The stock has a market capitalization of $150.24 billion, a PE ratio of 15.36 and a beta of 0.47. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.28.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, topping analysts’ consensus estimates of $0.79 by $0.08. The company had revenue of $16.65 billion for the quarter, compared to the consensus estimate of $16.94 billion. Pfizer had a net margin of 15.65% and a return on equity of 20.17%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. As a group, sell-side analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.5%. The ex-dividend date of this dividend is Friday, January 23rd. Pfizer’s payout ratio is 100.00%.

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a report on Thursday, January 22nd. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a research note on Wednesday, December 17th. Sanford C. Bernstein reissued a “market perform” rating and set a $30.00 price target on shares of Pfizer in a research report on Friday, October 31st. UBS Group initiated coverage on Pfizer in a report on Tuesday, January 6th. They issued a “neutral” rating and a $25.00 price target for the company. Finally, The Goldman Sachs Group reaffirmed a “neutral” rating and set a $26.00 price objective on shares of Pfizer in a research note on Wednesday, November 5th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $28.06.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: CEO Albert Bourla is doubling down on oncology with a roughly $23 billion post?COVID investment plan, positioning Pfizer as a major growth bet on cancer therapies — a strategic pivot investors see as a multi?year revenue driver. ‘We’ll save the world from cancer’: Inside Pfizer CEO’s $23 billion post?COVID bet on oncology
• Positive Sentiment: Pfizer struck a non?exclusive licensing agreement to access Novavax’s Matrix?M adjuvant technology (reported value ~$530M), which could boost future vaccine efficacy and pipeline value. Pfizer Inks $530M Deal for Novavax Matrix?M Adjuvant Technology
• Positive Sentiment: A bullish technical/forecast note projects upside toward ~$36.16, which can attract momentum and speculative buying. PFIZER Stock Holds Near $25.86 as Forecast Targets $36.16 Upside
• Neutral Sentiment: Pfizer is due to report Q4 and full?year 2025 results before the market opens Feb. 3; consensus Q4 estimates cited are ~$16.9B sales and $0.57 EPS — the upcoming print is the near?term catalyst. Should You Buy, Sell or Hold Pfizer Stock Ahead of Q4 Earnings?
• Neutral Sentiment: Zacks and other outlets report heightened retail/investor attention on PFE and provide deeper metric estimates ahead of earnings — increased search/coverage can amplify moves on the print. Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
• Neutral Sentiment: Background pieces (portfolio company lists, Wall Street metric breakdowns) add context but are unlikely to move the stock materially on their own. 7 Companies Owned by Pfizer
• Negative Sentiment: Critical commentary warns of valuation and execution risks (Seeking Alpha: “Buyer Beware”) and highlights that risks may outweigh near?term rewards, which can pressure sentiment. Pfizer: Buyer Beware, The Risk Outweighs The Reward
• Negative Sentiment: Media coverage of past management tactics (CEO comments on extreme COVID-era measures) and notes that PFE has recently underperformed peers may feed governance/PR concerns and short?term selling. Pfizer CEO says he used ‘emotional blackmail’ to get employees to achieve impossible goals during COVID-19 Pfizer Inc. stock underperforms Wednesday when compared to competitors

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.